ClinicalTrials.gg
CompletedNCT06684041Updated Jul 4, 2025

A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects

A Phase 1 interventional study of HRS-5965 capsule and HRS-5965 capsule placebo in Hemolytic Anemia, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This was a randomized, double-blind, single-dose, placebo-controlled phase I clinical trial. This study plans to conduct three dose groups of dose 1, dose 2, and dose 3. A total of 32 healthy subjects were planned to be enrolled.

02

Conditions studied

  • Hemolytic Anemia

Browse trials for

03

In context

Anemia, Hemolytic

56 studies on the registry are indexed under Anemia, Hemolytic; 16 are open to participants now.

This study's enrollment of 32 is below the median of 48 across 39 interventional studies indexed under Anemia, Hemolytic.

Browse Anemia, Hemolytic studies →

Lead sponsor

Chengdu Suncadia Medicine Co., Ltd. is the lead sponsor of 24 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form before any activities related to this trial, be able to understand the procedures and methods of this trial, and be willing to complete this trial in strict accordance with the clinical trial protocol.
  2. Aged between 18 and 45 years old (based on the time of signing the informed consent form), both males and females are eligible.
  3. The body weight of males ≥ 50 kg, and that of females ≥ 45 kg, and (BMI): 19 - 26 kg/m².
  4. During the screening period, there are no abnormalities in physical examination, vital signs, twelve - lead , frontal and lateral chest radiographs, abdominal ultrasound, and laboratory tests, or those with minor abnormalities but judged by the investigator to be of no clinical significance.
  5. During the screening period, antibody (HIV - Ab), treponema pallidum antibody, surface antigen (HBsAg), and virus antibody (HCV - Ab) are all negative.
  6. Complete the vaccination of Neisseria meningitidis and Streptococcus pneumoniae vaccines 2 weeks before the first administration of HRS - 5965.

Exclusion criteria

Exclusion Criteria:

  1. The researcher has determined that there may be diseases or medical conditions that affect the absorption, distribution, metabolism and excretion of drugs or reduce compliance.
  2. According to the judgment of the researcher, any physiological or psychological disease or condition that may increase the risk of the test, affect the subject's compliance with the protocol, or affect the subject's completion of the test.
  3. Those with a previous history of Neisseria meningitidis infection, or those whose first - degree relatives have a history of Neisseria meningitidis infection.
  4. Those with definite evidence of infection within 2 weeks before screening (positive etiological examination, or having received systemic antibiotic treatment), or those who have had a body temperature exceeding 38 °C.
  5. Subjects with abnormal serum electrolytes (hypokalemia, hypomagnesemia, hypocalcemia).
  6. Subjects with a history of convulsive disorders, long syndrome (including family history), syncope while swimming or any other type of syncope or history of loss of consciousness.
  7. Subjects with a previous history of heart disease, such as hypertension, atherosclerosis, heart failure, bradycardia or stroke, or those using a pacemaker.
  8. Those with a serum creatinine level exceeding the value, or those whose level does not exceed the upper limit but are judged by the investigator to be at risk of renal function impairment.
  9. Those with (ALT) or aspartate aminotransferase (AST) exceeding the upper limit of normal value (ULN), or with total exceeding 1.5 times the ULN.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Dose 1

    Drug: HRS-5965 capsule · Drug: HRS-5965 capsule placebo

  • Experimental
    Dose 2

    Drug: HRS-5965 capsule · Drug: HRS-5965 capsule placebo

  • Experimental
    Dose 3

    Drug: HRS-5965 capsule · Drug: HRS-5965 capsule placebo

Interventions

  • HRS-5965 capsule

  • DrugHRS-5965 capsule placebo

    HRS-5965 capsule placebo

06

What researchers measure

Primary outcomes

  1. Incidence of subjects with adverse events (AEs)

    Incidence of AEs, including any abnormal findings in vital signs, and/or physical examination and/or clinical laboratory assessments and/or 12-lead ECG evaluation.

    Time frame: Baseline up to seven days after the last dosing.

  2. QTcF: Baseline and placebo-adjusted QTcF after oral HRS-5965 capsules

    Time frame: Baseline up to 24 hours after dosing.

Secondary outcomes

  1. Area under the plasma concentration-time curve from time zero to the time of last quantifiable analyte concentration (AUC0-t) for HRS-5965

    Time frame: Baseline up to seven days after the last dosing.

  2. Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞) for HRS-5965

    Time frame: Baseline up to seven days after the last dosing.

  3. Maximum plasma concentration (Cmax) for HRS-5965

    Time frame: Baseline up to seven days after the last dosing.

  4. Time to reach maximum plasma concentration (Tmax) for HRS-5965

    Time frame: Baseline up to seven days after the last dosing.

  5. Terminal half-life (t1/2) for HRS-5965

    Time frame: Baseline up to seven days after the last dosing.

  6. Apparent clearance (CL/F) of HRS-5965 for administration subcutaneously

    Time frame: Baseline up to seven days after the last dosing.

  7. Apparent volume of distribution (V/F) of HRS-5965 for administration subcutaneously

    Time frame: Baseline up to seven days after the last dosing.

  8. Complement system alternative pathway (AP) inhibition efficiency

    Time frame: Baseline up to seven days after the last dosing.

07

Study locations

1 site
  • Zhongnan hospital of Wuhan University
    Wuhan, Hubei 430071, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Apr 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 12, 2024
StartActual
Nov 9, 2024
Primary completionActual
Apr 7, 2025
CompletionActual
Apr 7, 2025
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06684041
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Nov 9, 2024
Primary completion
Apr 7, 2025
Completion
Apr 7, 2025
Last update
Jul 4, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5965

Start the discussion